Menu Search
Equities

Stereotaxis Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RJR1:STU

Stereotaxis Inc

Actions
  • Price (EUR)1.69
  • Today's Change-0.04 / -2.31%
  • Shares traded20.00k
  • 1 Year change-23.87%
  • Beta1.3818
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

  • Revenue in USD (TTM)30.07m
  • Net income in USD-24.91m
  • Incorporated1990
  • Employees139.00
  • Location
    Stereotaxis Inc710 N Tucker Blvd, Ste 110ST. LOUIS 63101United StatesUSA
  • Phone+1 (314) 678-6100
  • Fax+1 (314) 678-6159
  • Websitehttps://www.stereotaxis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.